Genetics of malignant pleural mesothelioma: molecular markers and biologic targets.
MPM is a poorly understood lethal malignancy. Although the pathobiology of MPM is not completely elucidated, new genomic technology is likely to help shed light on the mechanisms of carcinogenesis through genome-wide screening of tumor-specific gene expression. Related efforts to identify the molecular markers of mesothelioma are pursued with the aim of refining current diagnostic capabilities, predicting prognosis, and designing appropriate trimodality programs. These new genomic tools also will assist efforts to tailor current adjuvant and neoadjuvant therapies, optimizing their effect and furthering research that may lead to new therapeutic options.
Bueno
Raphael
R
Department of Surgery, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Gordon
Gavin J
GJ
D017209:Apoptosis / Q000235:genetics; D014408:Biomarkers, Tumor; D002869:Chromosome Aberrations; D003937:Diagnosis, Differential; D020869:Gene Expression Profiling; D016147:Genes, Tumor Suppressor; D006801:Humans; D008654:Mesothelioma / Q000235:genetics* / Q000473:pathology; D009367:Neoplasm Staging; D010997:Pleural Neoplasms / Q000235:genetics* / Q000473:pathology; D011518:Proto-Oncogene Proteins / Q000235:genetics
D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins